WHO Issues Alert Over Severe Scarcity of Weight-Loss Jabs
Fewer than a tenth of people who could benefit from GLP-1 drugs including Wegovy have access to them, states the global health agency as it issues its inaugural guidance on the medications.
Considering more than one billion people worldwide currently classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be addressed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key hurdles to widespread availability to the injections that can aid individuals in losing substantial body mass, says the agency.
GLP-1 Therapy Supply Crisis
Despite the present most optimistic outlook, the supply of such drugs could only cover approximately 100 million people – under 10% of the global need, according to the health organization.
The recommendation calls on governments and firms to increase availability, via measures including voluntary licensing.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in several countries in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs imitate a natural hormone to reduce digestion speed, suppress the appetite and boost satiety so users eat less.
People commonly see weight reduction in the initial weeks of beginning the regular doses.
Research indicates people may put most of the weight back on within a year of discontinuing the drug, because their typical hunger return.
To be overweight or obese elevates your likelihood for experiencing health problems, like diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity impacts individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
